Original ContributionActivity of Pemetrexed (ALIMTA®, Multitargeted Antifolate, LY231514) in Metastatic Breast Cancer Patients Previously Treated with an Anthracycline and a Taxane: An Interim Analysis
References (20)
Treatment of breast cancer
N Engl J Med
(1998)- et al.
LY231514, a pyrrolo[2,3-d] pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes
Cancer Res
(1997) - et al.
LY231514, a novel pyrolopyrimidine antifolate that inhibits thymidylate synthase (TS)
Proc Annu Meet Am Assoc Cancer Res
(1992) 5-Fluoropyrimidines
Antimetabolites
- et al.
Comparative antitumor activity of the multitargeted antifolate LY231514 and the thymidylate synthase inhibitor ZD1694
Ann Oncol
(1996) - et al.
Activity of LY231514 against several enzymes in the folate-dependent pathways
Proc Annu Meet Am Assoc Cancer Res
(1996) - et al.
Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
Invest New Drugs
(1992) - et al.
Ten-year results of FAC adjuvant chemotherapy trial in breast cancer
Am J Clin Oncol
(1989) - et al.
Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration
J Clin Oncol
(1996)
Cited by (45)
Pemetrexed nephrotoxicity
2015, Bulletin du CancerA phase II trial of pemetrexed and gemcitabine in patients with metastatic breast cancer who have received prior taxane therapy
2010, Clinical Breast CancerCitation Excerpt :The addition of pemetrexed to either treatment schedule does not appear to confer an improvement in response rate over gemcitabine alone when used to treat heavily-pretreated patients.22,23,26 Similarly, adding gemcitabine to pemetrexed does not confer an improvement in response rate over pemetrexed alone as first-line therapy36 or in patients who have received anthracyclines and/or taxanes.12–14 A trend toward increased ORR was seen in ER– patients compared with ER+ patients on the 14-day schedule, consistent with previous studies,37 but this was not observed in patients on the 21-day schedule.
Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials
2010, Clinical Lung CancerCitation Excerpt :Pemetrexed (Alimta®, Eli Lilly and Company; Indianapolis, IN) is a third-generation antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase.1,2 This agent has demonstrated activity in a broad range of tumor subtypes.3–8 Pemetrexed has remarkable activity as a substrate for folylpolyglutamate synthetase, and its higher polyglutamate derivatives have comparable inhibition constants for thymidylate synthase.
Pleural Masses
2010, Medical Management of the Thoracic Surgery PatientFeasibility study of dose-dense biweekly administered pemetrexed in patients with nonsmall cell lung cancer
2010, Hematology/ Oncology and Stem Cell TherapyCitation Excerpt :The clinical benefit of such combinations is implied by early preclinical and clinical studies.21,22 In addition, on the assumption that the maximum tolerated dose of pemetrexed is not the one approved by the regulatory agencies and because even higher doses of 600 mg/m2 every 3 weeks were sufficiently tolerable in early phase 2 studies, our patients received a fixed dose of 1000 mg.23 A typical patient, assuming a 1.8 m2 body surface, receives 900 mg, whereas our smaller patient received the equivalent of 588 mg/m2 deemed to be safe.